--- title: "AstraZeneca’s camizestrant (Etcamah) misses primary goal in SERENA-4 first-line breast cancer trial" id: "news-news-stat-2ac82d9d42a92df8229b48a0" canonical_url: "https://medichelpline.com/news/news-news-stat-2ac82d9d42a92df8229b48a0" content_type: "medical_news_article" category: "Pharma" source_name: "STAT News" source_url: "https://www.statnews.com/2026/09/12/astrazeneca-breast-cancer-camizestrant-etcamah-serena-4-trail-failure/?utm_campaign=rss" published_at: "2026-09-12T07:09:28.000Z" license: "CC-BY-NC-4.0 / Informational Use" --- # AstraZeneca’s camizestrant (Etcamah) misses primary goal in SERENA-4 first-line breast cancer trial ## Metadata & Source Attribution - **Canonical URL:** https://medichelpline.com/news/news-news-stat-2ac82d9d42a92df8229b48a0 - **Category:** [Pharma](https://medichelpline.com/news/pharma.md) - **Reporting Source:** STAT News - **Original Source URL:** [Read Original Article](https://www.statnews.com/2026/09/12/astrazeneca-breast-cancer-camizestrant-etcamah-serena-4-trail-failure/?utm_campaign=rss) - **Published At:** 2026-09-12T07:09:28.000Z ## Executive Summary & Key Highlights - AstraZeneca reported that its oral breast cancer drug **camizestrant** (marketed as **Etcamah** in the U.S.) failed to beat standard care in a pivotal first-line study, the **SERENA-4** trial. - The study tested the drug in combination with another medicine for patients with **ER-positive, HER2-negative** advanced breast cancer who had not received prior systemic therapy for advanced disease. - The trial did not show superiority on a measure of how long patients went before disease worsening — the **progression-free** outcome. - Earlier in September 2026 the drug received accelerated approval in the U.S. as **Etcamah** for a narrower group of patients whose tumors develop a mutation linked to drug resistance. - AstraZeneca said it will continue clinical development of camizestrant, including studies in **early-stage** disease. Details about the SERENA-4 data and next regulatory or development steps were not reported in the source. ## In-Depth Reporting & Editorial Analysis ## AstraZeneca’s camizestrant misses primary endpoint in pivotal first-line trial AstraZeneca announced on Sept. 12, 2026, that its experimental oral breast cancer agent **camizestrant**, marketed in the U.S. as **Etcamah**, failed to outperform standard treatment in a pivotal trial evaluating the drug as a first-line therapy for advanced disease. The company said the study did not show a benefit on the trial’s key measure of how long patients went before their cancer progressed. The development is significant because the SERENA-4 study was designed to test whether camizestrant could expand beyond the narrower population for which the drug recently won accelerated U.S. approval. ## What the SERENA-4 trial tested SERENA-4 enrolled patients with **ER-positive, HER2-negative** advanced breast cancer who had not received another systemic therapy for their advanced disease. In the study, camizestrant was given in combination with another medicine and compared with standard treatment for that patient population. According to AstraZeneca’s announcement, the combination including camizestrant did not outperform the standard treatment on a measure of time to disease progression — the trial’s primary outcome. The source did not provide additional numerical results, subgroup findings, or safety details from SERENA-4. ## Regulatory background and the narrower approval Earlier in September 2026, camizestrant received accelerated approval from U.S. regulators under the brand name **Etcamah**. That approval applies to a more limited group of patients: those whose tumors develop a specific mutation associated with emerging resistance to prior therapy. The accelerated approval was granted before the SERENA-4 readout and covers patients with that mutation who need subsequent treatment. Had SERENA-4 met its primary endpoint, it could have supported a broader first-line indication and opened access to a larger patient population. The trial’s failure to show superiority therefore limits the immediate potential expansion of camizestrant beyond the narrowly defined accelerated-approval population. ## Why the result matters for patients and AstraZeneca The SERENA-4 outcome affects both clinical positioning and commercial prospects. A positive first-line trial could have established camizestrant as an option earlier in the treatment course for many patients with **ER-positive, HER2-negative** advanced breast cancer. Instead, the negative readout means the drug’s use may remain focused on the subgroup covered by the accelerated approval unless additional data support other indications. From a development perspective, a failed pivotal trial often leads companies to reassess study plans, regulatory strategies, and where to focus resources. The source reports that AstraZeneca plans to continue investigating camizestrant in other settings, including **early-stage** disease, but it did not detail specific trials, timelines, or next regulatory moves. ## Context on the patient population and typical endpoints Patients with **ER-positive, HER2-negative** breast cancer make up a common biologic subset of breast tumors. In advanced settings, clinical trials frequently use time-to-progression endpoints, such as progression-free survival, to evaluate whether a new therapy delays tumor growth compared with current standard treatments. The SERENA-4 trial used such a measure as its primary yardstick; according to AstraZeneca, camizestrant did not show a benefit on that endpoint. The source did not provide additional context such as median times, hazard ratios, confidence intervals, or adverse event profiles from the SERENA-4 data. Those details are typically included in company releases, regulatory filings, or peer-reviewed reports when sponsors disclose full results. ## What’s next for camizestrant (Etcamah) AstraZeneca said it will continue clinical development of camizestrant and pursue studies in **early-stage** disease. The source did not report further specifics: it did not name the early-stage trials, provide timelines, or indicate whether the company will seek regulatory discussions based on other ongoing studies. Because the drug already has an accelerated approval in the United States for a mutation-defined group of patients, Etcamah remains available in that narrow setting while broader first-line indications are uncertain following the SERENA-4 results. ## Takeaway AstraZeneca’s camizestrant failed to meet the primary endpoint in the pivotal SERENA-4 trial testing the drug as a first-line option for **ER-positive, HER2-negative** advanced breast cancer. The drug retains a U.S. accelerated approval for a mutation-defined subgroup, and AstraZeneca will continue testing camizestrant in other settings, including **early-stage** disease. The source did not provide detailed trial data or a timeline for next steps. Reporting and source This report is based on AstraZeneca’s Sept. 12, 2026 announcement and related coverage. Additional details that might appear in a full data release, regulatory filing, or scientific presentation were not reported in the source material. ## Navigation - [← Back to Pharma News](https://medichelpline.com/news/pharma.md) - [← All Medical News Categories](https://medichelpline.com/news.md) ## Medical & Regulatory Disclaimer > [!CAUTION] > MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations. > Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.